Dapirolizumab pegol explained
| Type: | mab |
| Target: | CD40 ligand |
| Unii: | N4606MB5HM |
| Cas Number: | 1416147-64-2 |
| Drugbank: | DB16131 |
Dapirolizumab pegol is "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus.[1] [2] [3]
Notes and References
- Chamberlain . Chris . Colman . Peter J . Ranger . Ann M . Burkly . Linda C . Johnston . Geoffrey I . Otoul . Christian . Stach . Christian . Zamacona . Miren . Dörner . Thomas . Urowitz . Murray . Hiepe . Falk . Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles . Annals of the Rheumatic Diseases . November 2017 . 76 . 11 . 1837–1844 . 10.1136/annrheumdis-2017-211388. 28780512 . 3577398 .
- Askanase . A. . Stach . C. . Brittain . C. . Stojan . G. . Furie . R. . Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data . Annals of the Rheumatic Diseases . 1 June 2023 . 82 . Suppl 1 . 272–273 . 10.1136/annrheumdis-2023-eular.1991 . 259786801 . en . 0003-4967. free .
- Furie . Richard A . Bruce . Ian N . Dörner . Thomas . Leon . Manuel Gustavo . Leszczyński . Piotr . Urowitz . Murray . Haier . Birgit . Jimenez . Teri . Brittain . Claire . Liu . Jiajun . Barbey . Catherine . Stach . Christian . Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus . Rheumatology . 6 May 2021 . 60 . 11 . 5397–5407 . 10.1093/rheumatology/keab381 . 33956056 . 9194804 . 1462-0324.
